-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On June 9th, the first batch of Covey's new coronavirus inactivated vaccines independently developed by the Institute of Medical Biology of the Chinese Academy of Medical Sciences (hereinafter referred to as the Institute of Biology of the Chinese Academy of Medical Sciences) was launched for emergency domestic use
.
The immunization procedure of this vaccine is the same as that of similar vaccines, with 2 doses in the whole course, with an interval of 2-4 weeks between each dose, and the vaccination age is 18 years and above
.
Image source: Phase I and II clinical trial data of the Institute of Biology of the Medical Academy.
Volunteers can quickly induce the body's immune response after being vaccinated.
The positive conversion rate of neutralizing antibody and anti-S protein antibody reached 96% and 96% after 14 days of full immunization.
99.
33%, effectively providing protection
.
The cross-neutralization test studies have shown that the antibodies induced by the vaccine-immunized body have the ability to cross-neutralize the new coronavirus epidemic strains from different sources
.
At present, the industrialization of the vaccine is steadily advancing, and the newly-built new crown inactivated vaccine production workshop in the Majinpu Vaccine Industry Base of the Institute of Biology of the Academy of Medical Sciences has been officially put into use
.
At the same time, the expansion project of the vaccine is also under construction.
It is expected to be completed and put into production by the end of the year.
By then, the annual output of the vaccine will increase to 500 to 1 billion doses
.
A few days ago, the Health Commission stated in an interview with the media that 21 new crown vaccines in China have entered clinical trials, 4 have been approved for conditional marketing, 3 have been approved for emergency use, and 8 vaccines have been approved for phase III clinical trials abroad.
In the trial, one mRNA vaccine was ethically approved abroad
.
In terms of the number of vaccine research and development, China is the world's first phalanx and has achieved comprehensive coverage of the technical routes of inactivated vaccines, recombinant protein vaccines, adenovirus vector vaccines, and nucleic acid vaccines in overseas clinical trials
.
This article is integrated from 21 Financial News, Science and Technology Daily
.
End's previous selection of onlookers will shut out the gods of death! "Nature Communications": Human life limit is between 120-150 years old.
Isn't it good to brush your teeth? The new study found that oral bacteria may activate the oncogene hot text "Three Children", this time it is "actual"! The spring of assisted reproduction is here! The first case in the world! After colorectal cancer patients received mRNA vaccine, cytokine storm appeared, or related to anti-PD-1 treatment, Nature's three consecutive heavyweights! Seeing through the "trick" of cancer cells, bringing new hope to patients with colorectal cancer Medical immunotherapy | Biosimilars | Vaccines | Drug resistance | Drug targets | Healthy life | Pharmaceutical company news | Drug inventory | Pharmaceutical technology | Drug side effects Basic Research/Translational Medicine Leukemia| Lung Cancer| Gastric Cancer| Colorectal Cancer| Liver Cancer| Breast Cancer| Pancreatic Cancer| Cardiovascular Disease| Neurodegenerative Disease| Intestinal Microbiological Medical Devices/Biotechnology In Vitro Diagnosis| Medical Devices| Bio-Nano| 3D Print|Gene testing|Single cell sequencing|Gene editing|Assisted reproduction|Artificial intelligence|Precision medicine policyAnticancer drugs|4+7 volume procurement|Consumables|Recording system|Registrant system|Health China|New edition of basic medicine catalog|AI Medical equipment | Telemedicine | Same stock market with different rights/capital IPO | Financing | Cooperation | Funds | Hong Kong Stock Exchange | Science and Technology Innovation Board | Growth Enterprise Market | R & D Investment | Acquisitions | Market & Consumption
.
The immunization procedure of this vaccine is the same as that of similar vaccines, with 2 doses in the whole course, with an interval of 2-4 weeks between each dose, and the vaccination age is 18 years and above
.
Image source: Phase I and II clinical trial data of the Institute of Biology of the Medical Academy.
Volunteers can quickly induce the body's immune response after being vaccinated.
The positive conversion rate of neutralizing antibody and anti-S protein antibody reached 96% and 96% after 14 days of full immunization.
99.
33%, effectively providing protection
.
The cross-neutralization test studies have shown that the antibodies induced by the vaccine-immunized body have the ability to cross-neutralize the new coronavirus epidemic strains from different sources
.
At present, the industrialization of the vaccine is steadily advancing, and the newly-built new crown inactivated vaccine production workshop in the Majinpu Vaccine Industry Base of the Institute of Biology of the Academy of Medical Sciences has been officially put into use
.
At the same time, the expansion project of the vaccine is also under construction.
It is expected to be completed and put into production by the end of the year.
By then, the annual output of the vaccine will increase to 500 to 1 billion doses
.
A few days ago, the Health Commission stated in an interview with the media that 21 new crown vaccines in China have entered clinical trials, 4 have been approved for conditional marketing, 3 have been approved for emergency use, and 8 vaccines have been approved for phase III clinical trials abroad.
In the trial, one mRNA vaccine was ethically approved abroad
.
In terms of the number of vaccine research and development, China is the world's first phalanx and has achieved comprehensive coverage of the technical routes of inactivated vaccines, recombinant protein vaccines, adenovirus vector vaccines, and nucleic acid vaccines in overseas clinical trials
.
This article is integrated from 21 Financial News, Science and Technology Daily
.
End's previous selection of onlookers will shut out the gods of death! "Nature Communications": Human life limit is between 120-150 years old.
Isn't it good to brush your teeth? The new study found that oral bacteria may activate the oncogene hot text "Three Children", this time it is "actual"! The spring of assisted reproduction is here! The first case in the world! After colorectal cancer patients received mRNA vaccine, cytokine storm appeared, or related to anti-PD-1 treatment, Nature's three consecutive heavyweights! Seeing through the "trick" of cancer cells, bringing new hope to patients with colorectal cancer Medical immunotherapy | Biosimilars | Vaccines | Drug resistance | Drug targets | Healthy life | Pharmaceutical company news | Drug inventory | Pharmaceutical technology | Drug side effects Basic Research/Translational Medicine Leukemia| Lung Cancer| Gastric Cancer| Colorectal Cancer| Liver Cancer| Breast Cancer| Pancreatic Cancer| Cardiovascular Disease| Neurodegenerative Disease| Intestinal Microbiological Medical Devices/Biotechnology In Vitro Diagnosis| Medical Devices| Bio-Nano| 3D Print|Gene testing|Single cell sequencing|Gene editing|Assisted reproduction|Artificial intelligence|Precision medicine policyAnticancer drugs|4+7 volume procurement|Consumables|Recording system|Registrant system|Health China|New edition of basic medicine catalog|AI Medical equipment | Telemedicine | Same stock market with different rights/capital IPO | Financing | Cooperation | Funds | Hong Kong Stock Exchange | Science and Technology Innovation Board | Growth Enterprise Market | R & D Investment | Acquisitions | Market & Consumption
